NCT07919509Not yet recruitingPhase 1
A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures
Pilot Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
This is a pilot project to determine the safety and feasibility of using panitumumab-IRDye800 to detect cancerous tissue compared to normal surrounding tissue in participants with ovarian cancer undergoing surgical resection. This study is an extension of the work previously done using this agent in patients with squamous cell carcinoma (SCC) of the head and neck, exploring its utility in a different cancer type.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- First submitted
- 30 Oct 2026
- Start date
- Nov 2026
- Primary completion date
- Nov 2027
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- Ovarian cancer
- NCT number
- NCT07919509
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 6
- From Nov 2026 to the primary completion date, Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
- Had within 6 months prior to enrollment: MI, CVA, or uncontrolled CHF
- Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
Other illness
- History of infusion reactions to any monoclonal antibody therapies
- Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
Lab values
- Evidence of QT prolongation on pretreatment EKG (greater than 440 ms in males or greater than 450 ms in females)
- Magnesium or potassium lower than the normal institutional values
Other
- Pregnant or breast-feeding
- TSH > 13 micro International Units/mL
Who the study is looking for
- Biopsy-confirmed diagnosis of ovarian cancer.
- Diagnosis of any stage.
- Diagnosis of any histology.
- Planning to undergo surgical resection via any modality (i.e., open, laparoscopic, robotic) with primary cytoreduction or interval debulking following neoadjuvant chemotherapy.
- Age ≥ 18 years
- ECOG 1
- Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results:
- Hemoglobin ≥ 9 gm/dL
- Absolute Neutrophil Count ≥ 1500
- White Blood Cell count > 3000/mm3
- Platelet count ≥ 100,000/mm3
- Serum creatinine ≤ 1.5 times upper reference range
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.